Loading cancer entity…
Loading cancer entity…
Clinical trials
74 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07614828 | Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in Malignant Melanoma of Nasal and Paranasal Mucosa | withdrawn | Phase 2 | 0 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05545969 | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma(Neo PeLeMM) | withdrawn | Phase 2 | 0 | Melanoma Institute AustraliaOTHER | 1 | Jun 26, 2024 |
| clinicaltrials |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jul 10, 2026source: clinicaltrials